Menu

Menu

May 3, 2012 8:30 ET | SOURCE: Regen BioPharma, Inc.

Bio-Matrix Subsidiary “First in Class” Approach to Stem Cell Medicine. Regen BioPharma Unveils Plan for Value Optimization of Nascent Stem Cell Patents

An overview of Regen BioPharma

Our management, scientific advisory board and intellectual property

Details around our intellectual property and its development

Our public filing and stock information

Our press releases and upcoming events

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

  • Products

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

  • Investor Relations

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

  • Company News

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

  • Contact us
  • Careers
  • Legal notice
  • Cookies policy
  • Privacy policy
  • Partnership
  • Covid-19
  • Press Releases
Twitter

What we do

Product Pipeline

Inverstor Relations

News & Updates

Management Team and Scientific Advisory Board

Careers

Contact Us

DuraCAR

KimerApt

HemaXellerate

dCellVax

tCellVax

DiffronC

Regulatory Filings

Featured News

News and Updates

Twitter
  • Contact us
  • Careers
  • Legal notice
  • Cookies policy
  • Privacy policy
  • Partnership
  • Covid-19
  • Press Releases

An overview of Regen BioPharma

Our management, scientific advisory board and intellectual property

Details around our intellectual property and its development

Our public filing and stock information

Our press releases and upcoming events

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

  • Products

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

  • Investor Relations

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

  • Company News

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

  • Contact us
  • Careers
  • Legal notice
  • Cookies policy
  • Privacy policy
  • Partnership
  • Covid-19
  • Press Releases
Twitter

What we do

Product Pipeline

Inverstor Relations

News & Updates

Management Team and Scientific Advisory Board

Careers

Contact Us

DuraCAR

KimerApt

HemaXellerate

dCellVax

tCellVax

DiffronC

Regulatory Filings

Featured News

News and Updates

Twitter
  • Contact us
  • Careers
  • Legal notice
  • Cookies policy
  • Privacy policy
  • Partnership
  • Covid-19
  • Press Releases